Vertex and CRISPR Therapeutics’ Casgevy became the first CRISPR gene therapy to be approved in the world after the UK’s MHRA granted conditional approval. Casgevy is indicated for the treatment of sickle cell disease and transfusion-dependent beta thalassemia, with the hope of being a potentially curative therapy for patients
With P4A you are
getting the best
Since 2015 we have been proud to partner and support clients who are at the forefront of creating groundbreaking new treatments and therapies.